255 completed, 88 unknown, 51 terminated, 28 recruiting. 470 Phase 2, 99 Phase 1, 79 Phase 3.
Follow Ischemia: new trials by email Literature Review of Ischemia trials Research Report on Ischemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease FGF-1, Placebo - Peripheral Arterial Disease, Stenosis | Phase 1 / Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 24 | 2028-10-15 | 2026-08-19 |
| Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment - No Reflow Phenomenon, Reperfusion Injuries, Myocardial | Phase 2 | Not yet recruiting | Al-Azhar University | 100 | 2027-01-01 | 2026-10-27 |
| Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period. Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium - Cerebral Infarction | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock Methylprednisone, Standard of Care (SOC) - Cardiogenic Shock, Heart Failure | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 30 | 2026-10-01 | 2026-08-13 |
| A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease VERVE-102, Placebo - Atherosclerosis, Cardiovascular Disease | Phase 2 | Not yet recruiting | Verve Therapeutics, Inc. | 175 | 2026-10-01 | 2026-09-24 |
| Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome Epidiolex 100 mg/mL Oral Solution - Sturge - Weber Syndrome (SWS) | Phase 2 | Recruiting | Johns Hopkins University | 10 | 2026-09-17 | 2026-10-02 |
| Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock istaroxime, placebo - Cardiogenic Shock | Phase 2 / Phase 3 | Recruiting | Seismic Pharmaceuticals Operations LLC | 600 | 2026-09-09 | 2026-09-23 |
| Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients empagliflozin, Placebo - ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI) | Phase 2 | Not yet recruiting | Rehman Medical Institute - RMI | 480 | 2026-09-01 | 2026-08-06 |
| Combined Antioxidant Therapy for Acute Myocardial Infarction Combined antioxidant therapy, Placebo - Acute Myocardial Infarction (AMI), ST Elevation (STEMI) Myocardial Infarction | Phase 2 | Not yet recruiting | University of Chile | 46 | 2026-09-01 | 2026-08-20 |
| Comparative Evaluation of Sustained meChanical AsPiration Thrombectomy and no Thrombus Modification for Pre-stent Thrombus bUrden Reduction in Patients With Acute Myocardial Infarction Study: the CAPTURE AMI Study Sustained thrombectomy, Percutaneous Coronary Intervention - STEMI - ST Elevation Myocardial Infarction | Phase 2 / Phase 3 | Recruiting | Oxford University Hospitals NHS Trust | 60 | 2026-07-08 | 2026-07-10 |
| Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction Xolatryp, Placebo - Myocardial Infarction, Reperfusion Injury | Phase 2 | Recruiting | Nyrada Pty Ltd | 300 | 2026-07-02 | 2026-10-06 |
| Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL Edaravone Dexborneol Sublingual Tablets - CADASIL | Phase 2 | Not yet recruiting | Huashan Hospital | 60 | 2026-07-01 | 2026-07-09 |
| Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Guanxinning Tablet(GXNT), Placebo - STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction | Phase 2 | Not yet recruiting | Beijing Anzhen Hospital | 70 | 2026-06-01 | 2026-06-02 |
| Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA) Minocycline hydrochloride capsule, Placebo capsules of Minocycline hydrochloride capsules - Acute Ischemic Stroke, Vessel Occlusion | Phase 2 / Phase 3 | Recruiting | Xiang Luo | 860 | 2026-05-21 | 2026-05-27 |
| Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction Recombinant Human Thymosin Beta 4 Injection (NL005), Placebo - Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall | Phase 2 | Not yet recruiting | Beijing Northland Biotech. Co., Ltd. | 189 | 2026-05-18 | 2026-05-14 |
| Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II Cord Blood Nucleated cells - Acute Myocardial Infarction (AMI) | Phase 2 | Not yet recruiting | HONYA Medical Co Ltd | 102 | 2026-03-30 | 2026-03-11 |
| Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial 2mg Baricitinib, 4mg Baricitinib, Placebo - Acute Ichemic Stroke, Anterior Cerebral Artery Stroke | Phase 2 / Phase 3 | Not yet recruiting | The First Affiliated Hospital of University of Science and Technology of China | 750 | 2026-03-17 | 2026-03-04 |
| A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction SGC001 injection, Placebo - Acute Anterior ST-Segment Elevation Myocardial Infarction | Phase 2 | Recruiting | Beijing Sungen Biomedical Technology Co., Ltd | 210 | 2026-03-09 | 2026-07-13 |
| Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study Ranolazine - STEMI (ST Elevation MI) | Phase 2 / Phase 3 | Recruiting | Federico II University | 100 | 2026-02-01 | 2026-03-11 |
| Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg, - Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia | Phase 2 | Recruiting | Aplagon Oy | 42 | 2026-01-29 | 2026-04-09 |
Showing 20 of 470. Sign in to see all of them.
Myocardial Infarction (178) · ST Elevation Myocardial Infarction (85) · Chronic Limb-Threatening Ischemia (70) · Stroke (59) · Coronary Artery Disease (41) · Cerebral Infarction (34) · Ischemic Stroke (33) · Heart Failure (32) · Peripheral Vascular Diseases (29) · Myocardial Ischemia (27) · Peripheral Arterial Disease (26) · Cardiovascular Diseases (25) · Acute Coronary Syndrome (23) · Shock, Cardiogenic (18)
Pathological Conditions, Signs and Symptoms (470) · Pathologic Processes (466) · Vascular Diseases (435) · Cardiovascular Diseases (429) · Necrosis (344) · Infarction (335) · Heart Diseases (277) · Myocardial Ischemia (262) · Arteriosclerosis (118) · Arterial Occlusive Diseases (110) · Myocardial Infarction (97) · Nervous System Diseases (92) · Central Nervous System Diseases (90) · Brain Diseases (87)
Sodium Chloride (15) · Aspirin (13) · Saline Solution (13) · Clopidogrel (12) · Atorvastatin (9) · Standard of Care (9) · Ticagrelor (9) · Percutaneous Coronary Intervention (7) · Tenecteplase (6) · Injections (5) · Eptifibatide (4) · Heparin (4) · Plasmalyte A (4) · Tissue Plasminogen Activator (4) · Transcranial Direct Current Stimulation (4)
University of Alberta (6) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (5) · Amaranth Medical Inc. (4) · AnGes USA, Inc. (4) · Hospices Civils de Lyon (4) · Johann Wolfgang Goethe University Hospital (4) · Mallinckrodt (4) · Mayo Clinic (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · University Health Network, Toronto (4) · University Medical Center Groningen (4) · Assistance Publique - Hôpitaux de Paris (3) · AstraZeneca (3) · Brigham and Women's Hospital (3) · Federal University of Paraíba (3)
United States (126) · Canada (42) · Germany (40) · China (39) · United Kingdom (31) · Netherlands (30) · Poland (30) · Spain (28) · France (26) · Italy (21) · Belgium (19) · Denmark (19) · South Korea (19) · Hungary (17) · Sweden (15)
Andreas M Zeiher, MD (4) · Antonio Colombo, MD (3) · Ali Eskandari, MD (2) · Antonio Abbate, MD, PhD (2) · Antonio Chacon, MD, PhD (2) · Christopher Chen, BMBCh, MRCP, FAMS, FRCPE (2) · Diego Martinez, MD, PhD (2) · Filippo Crea, MD (2) · Hossein Baharvand, PhD (2) · Hossein Vakili, M.D. (2) · Hyo-Soo Kim, MD (2) · Inmaculada Herrera, MD, PhD (2) · Joshua M Hare, MD (2)
PMID 35802393, PMID 22163120, PMID 17090774, PMID 19118718, PMID 21079055, PMID 21709062, PMID 22212857, PMID 22795280, PMID 29386200, PMID 37740111, PMID 9462531, PMID 10811917, PMID 12460865, PMID 15016484, PMID 15480537, PMID 15498829, PMID 16282547, PMID 16336965, PMID 16413875, PMID 16750696, PMID 16949482, PMID 16990383, PMID 16990385, PMID 17138963, PMID 17172279, PMID 17320744, PMID 17698683, PMID 18032779, PMID 18460663, PMID 18468545, PMID 18535785, PMID 18559698, PMID 18559703, PMID 18599344, PMID 18984888, PMID 19064521, PMID 19116389, PMID 19131132, PMID 19232907, PMID 19237716, PMID 19359665, PMID 19451353, PMID 19491213, PMID 19491386, PMID 19570514, PMID 19608137, PMID 19608488, PMID 19640572, PMID 19679246, PMID 19700099
2016 (5), 2009 (2), 2014 (2), 2015 (2), 2018 (2), 2025 (2), 2005 (1), 2008 (1), 2017 (1), 2019 (1), 2023 (1), 5UM1HL087318 (1), P50NS044148 (1), P50NS044227 (1), P50NS044283 (1)